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a b s t r a c t
Polymorphisms of genes involved in innate and adaptive immunity have become an object of major interest in
regard to hematopoietic stem cell transplantation (HSCT) complications. Regimen-related gastrointestinal
toxicity (RR-GIT) is the dominant complication during the pre-engraftment period and has been linked to
increased risk of graft-versus-host disease (GVHD) development. According to our hypothesis, functional var-
iants of genes participating in DNA damage response (DDR) may have an impact on the extent of tissue damage
caused by the conditioning regimen. In our single-center study, we analyzed 62 patients who underwent HSCT
from HLA-identical donors after reduced conditioning. The patients were genotyped for 5 single nucleotide
polymorphisms (SNPs, rs4585 T/G, rs189037 A/G, rs227092 T/G, rs228590 C/T, and rs664677 T/C) of the ATM
genedthe essential member of the DDR pathways, using allele-speciﬁc matrix-assisted laser desorption/ioni-
zation, time-of-ﬂight (MALDI-TOF) mass spectrometry assay. Because of almost absolute linkage disequilibrium
observed among all 5 SNPs, association of 2 major ATM haplotypes (ATM1/ATM2) with RR-GIT and acute GVHD
(aGVHD) was analyzed. Importantly, the univariate and multivariate analysis showed that patients homozygous
for ATM2 haplotype (rs4585*T, rs189037*A, rs227092*T, rs228590*C, and rs664677*T) are more likely to suffer
from high-grade RR-GIT than ATM1 homozygous patients. The association with aGVHD was not signiﬁcant. To
our knowledge, this is the ﬁrst report showing the ATM gene variability in relation to RR-GIT in the allogeneic
HSCT setting.
 2015 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) often provides the only curative option for many
malignant and nonmalignant hematological diseases.
Because of novel transplantation strategies and techniques,
the use of HSCT has increased during the last decade and
HSCT has become a standard therapeutic option for patients
who would not have previously been considered candidates
for HSCT. Reduced conditionings are becoming a more
frequent therapeutic option in elderly patients with high
comorbidity scores or in patients where immunoablation
rather than myeloablation is the primary aim. Despite all
advances in conditioning regimens and supportive care,
graft-versus-host disease (GVHD) represents the most
frequent cause of HSCT nonrelapse mortality and morbidity
[1]. Reports identifying genetic variants, such as single-
nucleotide polymorphisms (SNPs), of key regulatory cyto-
kines, chemokines, and genes involved in innate immunity
have appeared in the past decade, suggesting that pre-
transplantation genetic analysis could help to individualize
HSCT strategy [2,3].
Regimen-related gastrointestinal toxicity (RR-GIT) as a
result of tissue damage to the mucosal epithelium of the
gastrointestinal tract caused by the chemo(radio)therapy in
the pre-engraftment period has been proved to be signiﬁ-
cantly associated with increased risk of acute GVHD (aGVHD)
development [4-6]. Myeloablative conditioning regimens
were described to correlate with pronounced disruption of
the gut mucosa barrier and gastrointestinal toxicity [7,8]. In
mouse models, intensiﬁcation of the conditioning regimens
resulted in more severe gastrointestinal tissue damage,
triggering severe systemic aGVHD [9,10]. RR-GIT is accom-
panied by systemic release of damage and pathogen-
associated molecular patterns in combination with
proinﬂammatory mediators serving as stimuli and attrac-
tants for aGVHD immune cellular effectors. Alkylating agents
and ionizing radiation used in the HSCT conditioning cause
severe DNA damage. DNA damage response (DDR) signaling
pathways are sensed and orchestrated by ataxia telangiec-
tasia mutated (ATM) and ATM- and Rad3-related (ATR) ki-
nases regulating downstream processes, such as DNA repair,
cell cycle arrest, cellular senescence, and apoptosis [11,12].
SNPs of the ATM gene have been object of interest in
oncology of solid tumors and radiation-related complica-
tions [13-18]. In the setting of allogeneic HSCT, only a single
case report has been published in relation to ATM gene
observing severe skin radiotoxicity in an allogeneic trans-
plant recipient with a heterozygous ATM gene mutation [19].
Based on a literature search, we selected 5 candidate SNPs of
the ATM gene (rs4585 TG, rs189037 AG, rs227092 TG,
rs228590 CT, and rs664677 TC) that had signiﬁcant clinical
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consequences [13-18]. In our analysis, we focused on the
association of investigated SNPs of the ATM gene region with
RR-GIT and aGVHD development.
MATERIALS AND METHODS
Study Group
In our single-center study, we analyzed 62 patients (female, 44%)
undergoing HSCT from HLA-identical donors for hematological malig-
nancy between 2009 and 2014. The median age was 53.5 (range, 24 to 62)
years. A nonmyeloablative regimen was used in 12 patients (20%), and
reduced-intensity and reduced-toxicity regimens were used in 30 (48%)
and 20 (32%) patients, respectively. Patients underwent HSCT for the
following hematological malignancies: acute myeloid leukemia, 23 pa-
tients (37%); acute lymphoblastic leukemia, 8 patients (13%); chronic
lymphoblastic leukemia, 9 patients (15%); myelodysplastic syndrome, 7
patients (11%); non-Hodgkin lymphoma, 4 patients (6%); chronic myeloid
leukemia, 4 patients (6%); chronic myelomonocytic leukemia, 3 patients
(5%); myeloﬁbrosis (MF) 2 patients (3%), and other hematological disor-
ders 2 patients (3%). The European Society for Blood and Marrow
Transplantation (EBMT) risk score was used to assess the actual pre-
transplantation risk of every patient [20] because the recipient’s age,
time interval from diagnosis to transplantation, and disease status may
have an impact on RR-GIT. The median EBMT score of the study group
was 3 (range, 1 to 6). Classiﬁcation and terminology of nonmyeloablative
and reduced-intensity regimens were used as established by Bacigalupo
et al. [21]. In our study, reduced-intensity regimens combining ﬂudar-
abine with 2-day busulfan (total dose 8 mg/kg orally, or 6.4 mg/kg
intravenously) or ﬂudarabine with melphalan (total dose 100 to 140 mg/
m2 intravenously) were used. Reduced-toxicity regimens combining ﬂu-
darabine and 3-day busulfan (total dose 12 mg/kg orally or 9.6 mg/kg
intravenously) were used as published by Mohty et al. [22]. Gastroin-
testinal toxicity (stomatitis, nausea/vomiting, and/or diarrhea) was
graded according to World Health Organization criteria (grades 0 to IV)
[23] during the pre-engraftment period, where engraftment was deﬁned
as absolute neutrophil count > .5  109/L for 3 subsequent days. The
patients were questioned and checked for RR-GIT signs and symptoms on
daily basis. The oral cavity was checked for signs of stomatitis. Pain was
measured using the standardized pain scale (range, 0 to 10). Episodes of
vomiting and/or diarrhea were counted per 24 hours and their volumes
were measured. Grade of RR-GIT was recorded in every patient when
leaving the bone marrow transplantation unit. In every patient with any
signs and/or symptoms of RR-GIT (oral pain/stomatitis, vomiting, diar-
rhea), microbial cultivations and PCR detection of viral DNA (Cytomega-
lovirus [CMV], Epstein-Barr virus [EBV], Human herpesvirus 6 [HHV6],
Parvovirus B 19 [PB19], Adenovirus [ADV]) from peripheral blood and/or
the involved tissues were performed to exclude infectious causes. Also,
the patients were checked for presence of adenoviral, rotaviral, and
clostridium antigens, including clostridium toxin in stools. GVHD pro-
phylaxis was done by solo cyclosporine A in 57 patients (92%), cyclo-
sporine A with mycophenolate mofetil in 4 patients (6%), and
cyclosporine A with short-term methotrexate in 1 patient (2%). In vivo T
cell depletion with thymoglobulin was used in 43 patients (70%). All
patients were allografted from HLA-identical donors (45% from related
donors) with median age of 39.5 (range, 18 to 63) years. The female
donor/male recipient combination represented 13% of all pairs. The grafts
contained a median of 4.6 (range, 2.8 to 8.0)  106 CD34þcells/kg and
median of 6.8 (range, 1.9 to 27.1)  108 mononuclear cells (MNC)/kg. The
diagnosis of aGVHD was based on clinical manifestation and histopath-
ological ﬁndings during the postengraftment period. Glucksberg’s criteria
were used in grading [24].
Before the start of the conditioning, every patient was tested for the 5
selected SNPs located in the ATM gene region. All patients gave signed
informed consent with the study procedure approved by the institutional
review board.
Genetic Analysis
SNPs of the ATM genewere selected based on previous studies regarding
their association with susceptibility to various diseases (namely, tumors)
and complications of therapy, eg, radiotoxicity (Table 1). ATM SNPs with
minor allele frequency higher than 10% in European populations were
included in this study (source of data: dbSNP Short Genetic Variation at
http://www.ncbi.nlm.nih.gov/projects/SNP). Genomic DNA was isolated
from EDTA-treated peripheral blood using Blood DNA 500 extraction kit
with an Arrow pipeting instrument (DiaSorin, Dublin, Ireland) according to
the manufacturer protocol. Genotyping was performed with Sequenom
MassARRAY platform using allele-speciﬁc MALDI-TOF mass spectrometry
assay (Sequenom, San Diego, CA). Primers were designed using the Seque-
nom SNP Assay Design software version 3.0 for iPLEX reactions. The
sequences of ampliﬁcation and extension primers used for genotyping of
investigated SNPs are listed in Table 1. The protocol and reaction conditions
were in accordance with the manufacturer [25].
Statistical Analysis
First, univariate analysis was performed to ﬁnd out if there is signiﬁcant
difference in RR-GIT and aGVHD among the patient groups with different
ATM SNPs genotype proﬁles. The asymptotic Pearson’s chi-square test was
used in cross tabulation. Cross tabulation was also used to assess the inde-
pendence of any 2 categorical variables (eg, RR-GIT and the type of condi-
tioning, see the Results section). To compare continuous predictors among
patient subgroups (eg, the distribution of age in different ATM SNPs geno-
type proﬁle groups), the Kruskal-Wallis test was used.
Second, to assess the combined inﬂuence of various predictors on RR-
GIT occurrence, standard logistic regression was used in multivariate anal-
ysis with the following predictors: type of conditioning (reduced toxicity,
Table 1
Overview of Selected SNPs of the ATM Gene and Combined ATM Five Loci Genotypes Observed in the Studied Population
Part A. Investigated SNPs of the ATM Gene and the Ampliﬁcation and Extension Primers Used for Their Genotyping by Means of Allele-speciﬁc MALDI-TOF
Mass Spectrometry Assay
ATM SNP SNP Category Ampliﬁcation Primers Extension Primer Ref.
rs4585 G/T UTR-3* ACGTTGGATGGCAAATAAAAGCAAAGAGG GAGGAAAAACTTTGGACA [16]
ACGTTGGATGCAAACCAATATACTGGCTTTC
rs189037 A/G UTR-5* ACGTTGGATGGTCAAAGTAGTATCAACCGC CCTCTCGCCTCCTCCCG [13,15,17,18]
ACGTTGGATGGCTAACGGAGAAAAGAAGCC
rs227092 G/T UTR-3* ACGTTGGATGCACTGAGTGATCTTACTAGG TGATCTTACTAGGAAAAATCCAAATA [15]
ACGTTGGATGAGCCTGGGTGACAAGAGCG
rs228590 C/T Intron ACGTTGGATGAGCAGATGGCTCTGATTCTC GGTCTCTGATTCTCTTCTCCTTT [17]
ACGTTGGATGGCAGAGTAAAGCGGAAGTTG
rs664677 C/T Intron ACGTTGGATGGGCATATTCCACATAATGAC AAAGACATATTGGAAGTAACTTA [16,18]
ACGTTGGATGAAAGCACTCAGAAAACTCAC
*UTR-3/UTR-5: 30/50 untranslated region of the ATM gene
Part B. Combined ATM Five-loci Genotypes Observed in the Studied Population
rs4585 rs189037 rs227092 rs228590 rs664677 N
GG GG GG TT CC 14
GT GA GT CT CT 27
TT AA TT CC TT 18
All 5 ATM gene SNPs were selected based on previous studies describing their association with susceptibility to several diseases (tumors mostly) and therapy-
related complications. Primers were designed using the Sequenom SNP Assay Design software version 3.0 for iPLEX reactions (Part A). Only 3 common combined
5-loci genotypes listed in the table were observed in studied population (except 2 patients with difference in single SNP) suggesting almost absolute linkage
disequilibrium among all 5 ATM SNPs. Accordingly, 2 major ATM haplotypes were deﬁned and utilized for analysis with RR-GIT (ATM1: rs4585*G/rs189037*G/
rs227092*G/rs228590*T/rs664677*C, ATM2: rs4585*T/rs189037*A/rs227092*T/rs228590*C/rs664677*T) (Part B).
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reduced intensity, nonmyeloablative conditioning), EBMT risk score
(dichotomic, EBMT 3, and EBMT 4), active disease (dichotomic), sex, and
ATM genotype proﬁle (3 categories). The outcome variable was dichoto-
mized to 2 levels: RR-GIT  II (coded as 0), and RR-GIT  III (coded as 1). A
similar model was built for aGVHD. Distribution of ATM genotypes was
tested for conformity with the Hardy-Weinberg equilibrium by chi-square
test. All statistical analyses were performed using the Statistica software
and the R software. The signiﬁcance level of all tests was set to .05.
RESULTS
The median post-transplantation follow-up was 1.2
(range, .1 to 4.5) years. Of the 62 patients, 39 patients (63%)
are still alive and 23 (37%) patients have died (11 patients
died of transplantation-related complications). RR-GIT grade
III and IV was documented in 25 patients (47%), RR-GIT grade
I and II in 23 patients (33%), and no RR-GIT in 14 patients
(20%). Twenty patients (32%) developed aGVHD. Acute GVHD
grade I and II and III and IV were observed in 16 (26%) and 4
(6%) patients, respectively.
The following 5 ATM SNPs were studied: rs4585, rs189037,
rs227092, rs228590, and rs664677. Distribution of genotypes
in all investigated SNPs was concordant with the Hardy-
Weinberg equilibrium expectations (P > .05). Almost
absolute linkage disequilibriumwas observed among all 5 in-
dividual SNPs that resulted in 3 common combined 5-loci
genotypes in the studied population (Table 1). Consequently,
the genotypes of all but 2 patients may be explained
by combination of 2 major ATM gene haplotypes
(ATM1: rs4585*G/rs189037*G/rs227092*G/rs228590*T/rs664
677*C, ATM2: rs4585*T/rs189037*A/rs227092*T/rs228590*C/
rs664677*T). Based on the difference in single SNP genotype,
the proﬁle in 2 patients would not match any combination of
ATM1/ATM2 haplotypes (suggesting presence of rare haplo-
type), and, therefore, we excluded them from the haplotype
analysis. Complete genotype proﬁle could not be obtained in 1
patient who was excluded from the analyses.
To exclude any nonhomogeneous distribution of RR-GIT
risk factors among patients carrying the 3 ATM genotypes,
we compared all 3 ATM genotype proﬁles in terms of age, sex,
EBMT score, and conditioning regimens (Table 2). No signif-
icant differences were found here.
The ATM genotype proﬁle was found to be signiﬁcantly
associated (P ¼ .012) with RR-GIT in the following way: pa-
tients homozygous for the ATM1 haplotype are less probable
to suffer from high-grade RR-GIT than patients in the group
of ATM2 homozygotes (Figure 1). Patients with the ATM
heterozygous genotype proﬁle (ATM1/ATM2) tend to exhibit
moderate RR-GIT (grades I and II).
Further, the effect of ATM genotype proﬁle was combined
with the inﬂuence of other predictors on RR-GIT in multi-
variate analysis. By means of a logistic regression model, the
ATM2/ATM2 genotype was conﬁrmed to be strongly associ-
ated with high-grade RR-GIT (odds ratio, 23; 95% conﬁdence
interval, 3 to 380; P ¼ .01).
Theassociationof theATMgenotypeproﬁlewithaGVHDwas
tested in the full multivariate logistic model; however, none of
the above deﬁned predictors reached statistical signiﬁcance. In
the univariate analysis, the ATM2/ATM2 genotype used as a
single predictor tends to increase the probability of aGVHD
development; however, the effect is not signiﬁcant (P ¼ .14).
CONCLUSIONS
Asmentioned in the introduction, ATM plays a crucial role
in identifying DNA lesions and orchestrating the DDR
signaling. According to our hypothesis, in patients exposed to
conditioning-induced genotoxic stress, genetic variations of
the ATM gene may inﬂuence the extent of tissue damage and,
subsequently, also the RR-GIT. To our knowledge, this is the
ﬁrst report describing the association of the ATM gene with
RR-GIT in allogeneic HSCT setting.
One of the SNPs investigated in our study, namely ATM-
rs189037, is known to be situated in the promoter region of
the ATM gene. Although the nucleotide switch (G>A) does
not encode for amino acid change, it may cause different
binding afﬁnity of transcriptional factors and, thus, exhibit
different levels of mRNA expression [26,27]. Decreased levels
of ATM mRNA associated with the ATM-rs189037 AA geno-
type were observed in lung tissues by Zhang et al. [28].
Importantly, ATM-rs189037 AA is involved in the ATM2/
ATM2 genotype, which has been shown to predispose to
high-grade RR-GIT in our study. Moreover, the effect of the
ATM2/ATM2 genotype proﬁle remains signiﬁcant, even after
accounting for the effects of other predictors. Accordingly,
we hypothesize that patients carrying ATM2/ATM2 genotype
may be defective in their DDR mechanisms because of
insufﬁcient ATM production and, thus, be at higher risk of
conditioning-induced tissue damage.
Table 2
RR-GIT Risk Factors Distribution in ATM Genotype Proﬁles
Risk Factor ATM1/1 ATM1/2 ATM2/2 P Value
Age at HSCT, median
(range), yr
53 (34-61) 54 (24-61) 53 (24-62) .989
EBMT score, median
(range)
3 (1-6) 4 (1-6) 3 (1-5) .417
Male/female ratio 7/7 16/11 10/8 .851
Reduced-toxicity
conditioning, n (%)
3 (21%) 9 (32%) 8 (44%) .357
Reduced-intensity
conditioning, n (%)
7 (50%) 15 (54%) 7 (39%) .547
Nonmyeloablative
conditioning, n (%)
4 (29%) 4 (14%) 3 (17%) .720
The Kruskal-Wallis test was used to compare the median age and the EBMT
score among the 3 ATM genotype proﬁles. Cross tabulation was applied to
assess the independence of sex and all 3 types of conditioning regimens.
Figure 1. Three columns representing each ATM genotype with marked RR-
GIT distribution (no RR-GIT, lower part; RR-GIT I and II, middle part; and
RR-GIT III and IV, upper part of columns). The numbers inside of every column
represent the actual number of patients. Patients with the ATM1/1 genotype
are less probably to suffer from high-grade RR-GIT than patients with ATM2/2
genotype (P ¼ .012). Patients in the ATM1/2 group tend to exhibit moderate
RR-GIT (grade I and II). ATM1/1 indicates homozygotes for ATM1 haplotype;
ATM2/2, homozygotes for ATM2 haplotype; ATM 1/2, heterozygotes.
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RR-GIT differed among the conditioning regimens used
in the study cohort. Patients conditioned with non-
myeloablative regimens had a lower rate of high-grade RR-
GIT than patients conditioned with reduced-intensity or
reduced-toxicity regimens. In contrast, we observed the
highest rate of high-grade RR-GIT in patients conditioned
with reduced-toxicity regimens (data not shown). Raida et al.
reported increased rate of mucosal toxicity in patients
conditioned with reduced-toxicity regimen (ﬂudarabine
with 3-day busulfan) compared with reduced-intensity
regimens (ﬂudarabine with melphalan) [29]. Variability in
organ toxicity and aGVHD rates among the different types of
reduced-intensity regimens (ﬂudarabine with 2-day
busulfan and ﬂudarabine with melphalan) were described
by Shimoni et al. [30].
Goldberg et al. ﬁrst documented increased risk of aGVHD
in patients with conditioning-induced gastrointestinal
toxicity measured by diarrhea volume [5]. Johansson et al.
described less disruption of the gut mucosa barrier and less
gastrointestinal toxicity after reduced-intensity condition-
ings than after myeloablative conditioning [31].
Furthermore, this observation was updated by the fact
that both intestinal barrier disruption and clinical gastroin-
testinal toxicity, according to World Health Organization
criteria, predict aGVHD severity [6]. However, the observed
signiﬁcant decrease in RR-GIT after reduced conditioning
was not followed by a signiﬁcant decrease in aGVHD, con-
ﬁrming that there are other signiﬁcant factors involved in
aGVHD development. Obviously, it is natural to ask whether
SNPs of the ATM gene may also have an impact on aGVHD
development. However, the effect of the ATM gene SNPs was
not conﬁrmed in our study cohort. This may partially be
explained by the limited number of patients included in the
analysis. Moreover, GVHD is an immunologically mediated
complication and genetic variations of mediators down-
stream of the ATM in the ATM-NFkB-IL6 signaling are known
to be implicated. Our preliminary results suggest that
selected SNPs of the NF-kB1 gene are signiﬁcantly associated
with aGVHD development (data not shown). Thus, ATM gene
SNPs seem to be more tightly associated with the initial
tissue damage rather than the consequent ﬁnal immuno-
logical complication.
It has been shown that persistent DDR signaling is
accompanied by proinﬂammatory secretion and initiates the
irreversible cell cycle arrest called cellular senescence [32].
According to our hypothesis, these senescent cells may
become the inexhaustible source of proinﬂammatory
secretion stimulating graft’s immune cellular effectors and,
thus, triggering the GVHD activity. The ATM activation in
response to DNA damage induces under certain conditions
expression of various proinﬂammatory cytokines, such as IL-
6 or IL-8 [32]. IL-6 is 1 of many senescence-associated cy-
tokines [33] and in the allogeneic HSCT setting, plays a
crucial role in the conditioning-induced cytokine storm
[34,35]. In our previous studies, SNPs of the promoter region
of the IL-6 gene at position 174 (G/C) were found to be
associated with an increased risk of aGVHD and a decreased
overall survival in the patients allografted from HLA-
identical sibling donors [36,37]. The regulation of IL-6
secretion seems to be controlled not only by the ATM ki-
nase but also through the NF-kB activation [32,38]. We
suggest that ATM-NFkB-IL6 signaling may merit further
investigation in context of GVHD pathophysiology and may
bring novel clinical information to assess patients’ pre-
transplantation risk.
Our pilot results suggest thatATM genepretransplantation
analysis could be of beneﬁt when tailoring the patient’s
therapy. However, this needs to be conﬁrmed in prospective
independent trials.
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a b s t r a c t
The Brazil Ministry of Health maintains a Registry of Bone Marrow Donors that corresponds to approxi-
mately 12% of the Bone Marrow Donors Worldwide registry. This registry contains information on
ethnicity (by self-assessment of color) and HLA-A, -B, and -DRB1 type. The self-assessment of color tool has
been extensively used for admixed population characterization. In this context, Brazil represents a highly
admixed population, resulting from 5 centuries of colonization and interbreeding, mainly, but not exclu-
sively, among Native Americans, Europeans, and Africans. Here we evaluated self-assessed skin color and
HLA genetic information from 71,291 bone marrow donors of southern Brazil to verify how likely is the
HLA proﬁling correspondence within and between self-assessed color groups. We found that HLA itself
was a better ancestry indicator than was self-assessed color. Therefore, self-assessment of color in highly
admixed populations, such as that of Brazil, is not indicative of higher correspondence in the HLA proﬁles
within skin color groups.
 2015 American Society for Blood and Marrow Transplantation.
INTRODUCTION
The HLA system is very useful in population genetics
studies, because HLA haplotypes and alleles are distributed
at different frequencies in populations or ethnic groups
around theworld [1-3]. Therefore, it is expected that patients
needing an allogeneic stem cell transplant are most likely to
ﬁnd their HLA-matched donor within their own population
or ethnic group.
The Brazil Ministry of Health maintains a Registry of Bone
Marrow Donors (REDOME) and a registry for people needing
transplants (National Register of Bone Marrow Recipients).
The information in these registries includes ethnicity (by
self-assessment of color) and genetic typing of HLA-A, -B,
and -DRB1 [4]. REDOME is part of the Bone Marrow Donors
Worldwide registry, which has over 24 million donors as
recorded by October 2014 [5]. As of June 2014 more than 3.2
million donors were registered in the REDOME registry [4],
which correspond to approximately 12% of the Bone Marrow
Donors Worldwide registry.
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